FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Questions Y-mAbs Neuroblastoma Treatment Efficacy

FDA raises efficacy questions about a Y-mAbs BLA for I-omburtamab to treat pediatric patients with CNS/leptomeningeal metastases from neuroblastoma.

latest-news-card-1
Medical Devices

Digital Health Regulatory Science Opportunities

The CDRH Digital Health Center of Excellence releases a document highlighting topics of interest for regulatory science research and partnerships.

latest-news-card-1
Human Drugs

GSK Scraps Monoclonal Antibody Development for RA

GSK decides not to seek FDA approval for otilimab, an investigational monoclonal antibody targeting granulocyte-macrophage colony-stimulating factor a...

latest-news-card-1
Federal Register

Info Collection on 3rd Party Review Program

Federal Register notice: FDA sends to OMB an information collection extension entitled 510(k) Third-Party Review Program.

latest-news-card-1
Human Drugs

FY 2023 GDUFA Research Priorities

FDA posts eight generic drug research priority initiatives for FY 2023.

latest-news-card-1
Medical Devices

Baxter WatchCare Urgent Correction

FDA says Baxter International has issued an urgent medical device correction for its WatchCare incontinence system that may cause radio interference w...

latest-news-card-1
Medical Devices

Developing, Responding to Device Deficiencies Guidance

FDA publishes a guidance to help agency staff request additional information needed to make decisions on medical device marketing applications.

latest-news-card-1
Medical Devices

MDIC Cybersecurity Maturity Benchmark Report

The Medical Device Innovation Consortium releases its first medical device manufacturer benchmark report on cybersecurity maturity.

latest-news-card-1
Medical Devices

Califf Hoping for LDT Legislation

FDA commissioner Robert Califf says he hopes Congress will include regulation of laboratory-developed tests and several other issues in a December fun...

latest-news-card-1
Human Drugs

FDA Postpones Meeting on OTC Birth Control Pill

FDA postpones an 11/18 joint advisory committee that was going to vote on a Laboratoire HRA Pharma supplemental NDA for Opill (norgestrel, 0.075 mg), ...